Silencing of ribonucleotide reductase subunit M1 potentiates the antitumor activity of gemcitabine in resistant cancer cells

References

• Wong A, Soo RA, Yong WP, Innocenti F. Clinical pharmacology and pharmacogenetics of gemcitabine. Drug Metab Rev 2009; 41:77 - 88; http://dx.doi.org/10.1080/03602530902741828; PMID: 19514966
   PubMed Web of Science ®Google Scholar
• Long J, Zhang Y, Yu X, Yang J, LeBrun DG, Chen C, et al. Overcoming drug resistance in pancreatic cancer. Expert Opin Ther Targets 2011; 15:817 - 28; http://dx.doi.org/10.1517/14728222.2011.566216; PMID: 21391891
   PubMed Web of Science ®Google Scholar
• Thelander L, Reichard P. Reduction of ribonucleotides. Annu Rev Biochem 1979; 48:133 - 58; http://dx.doi.org/10.1146/annurev.bi.48.070179.001025; PMID: 382982
   PubMed Web of Science ®Google Scholar
• Baker CH, Banzon J, Bollinger JM, Stubbe J, Samano V, Robins MJ, et al. 2′-Deoxy-2′-methylenecytidine and 2′-deoxy-2′,2′-difluorocytidine 5′-diphosphates: potent mechanism-based inhibitors of ribonucleotide reductase. J Med Chem 1991; 34:1879 - 84; http://dx.doi.org/10.1021/jm00110a019; PMID: 2061926
   PubMed Web of Science ®Google Scholar
• Heinemann V, Xu YZ, Chubb S, Sen A, Hertel LW, Grindey GB, et al. Inhibition of ribonucleotide reduction in CCRF-CEM cells by 2′,2′-difluorodeoxycytidine. Mol Pharmacol 1990; 38:567 - 72; PMID: 2233693
   PubMed Web of Science ®Google Scholar
• Jordheim LP, Guittet O, Lepoivre M, Galmarini CM, Dumontet C. Increased expression of the large subunit of ribonucleotide reductase is involved in resistance to gemcitabine in human mammary adenocarcinoma cells. Mol Cancer Ther 2005; 4:1268 - 76; http://dx.doi.org/10.1158/1535-7163.MCT-05-0121; PMID: 16093443
   PubMed Web of Science ®Google Scholar
• Davidson JD, Ma L, Flagella M, Geeganage S, Gelbert LM, Slapak CA. An increase in the expression of ribonucleotide reductase large subunit 1 is associated with gemcitabine resistance in non-small cell lung cancer cell lines. Cancer Res 2004; 64:3761 - 6; http://dx.doi.org/10.1158/0008-5472.CAN-03-3363; PMID: 15172981
   PubMed Web of Science ®Google Scholar
• Bergman AM, Eijk PP, Ruiz van Haperen VW, Smid K, Veerman G, Hubeek I, et al. In vivo induction of resistance to gemcitabine results in increased expression of ribonucleotide reductase subunit M1 as the major determinant. Cancer Res 2005; 65:9510 - 6; http://dx.doi.org/10.1158/0008-5472.CAN-05-0989; PMID: 16230416
   PubMed Web of Science ®Google Scholar
• Bepler G, Kusmartseva I, Sharma S, Gautam A, Cantor A, Sharma A, et al. RRM1 modulated in vitro and in vivo efficacy of gemcitabine and platinum in non-small-cell lung cancer. J Clin Oncol 2006; 24:4731 - 7; http://dx.doi.org/10.1200/JCO.2006.06.1101; PMID: 16966686
   PubMed Web of Science ®Google Scholar
• Oguri T, Achiwa H, Sato S, Bessho Y, Takano Y, Miyazaki M, et al. The determinants of sensitivity and acquired resistance to gemcitabine differ in non-small cell lung cancer: a role of ABCC5 in gemcitabine sensitivity. Mol Cancer Ther 2006; 5:1800 - 6; http://dx.doi.org/10.1158/1535-7163.MCT-06-0025; PMID: 16891466
   PubMed Web of Science ®Google Scholar
• Chung WG, Sandoval MA, Sloat BR, Lansakara-P DS, Cui Z. Stearoyl gemcitabine nanoparticles overcome resistance related to the over-expression of ribonucleotide reductase subunit M1. J Control Release 2012; 157:132 - 40; http://dx.doi.org/10.1016/j.jconrel.2011.08.004; PMID: 21851843
   PubMed Web of Science ®Google Scholar
• Gong W, Zhang X, Wu J, Chen L, Li L, Sun J, et al. RRM1 expression and clinical outcome of gemcitabine-containing chemotherapy for advanced non-small-cell lung cancer: A meta-analysis. Lung Cancer 2011; PMID: 21889227
   PubMed Web of Science ®Google Scholar
• Nakahira S, Nakamori S, Tsujie M, Takahashi Y, Okami J, Yoshioka S, et al. Involvement of ribonucleotide reductase M1 subunit overexpression in gemcitabine resistance of human pancreatic cancer. Int J Cancer 2007; 120:1355 - 63; http://dx.doi.org/10.1002/ijc.22390; PMID: 17131328
   PubMed Web of Science ®Google Scholar
• Ohtaka K, Kohya N, Sato K, Kitajima Y, Ide T, Mitsuno M, et al. Ribonucleotide reductase subunit M1 is a possible chemoresistance marker to gemcitabine in biliary tract carcinoma. Oncol Rep 2008; 20:279 - 86; PMID: 18636187
   PubMed Web of Science ®Google Scholar
• Akita H, Zheng Z, Takeda Y, Kim C, Kittaka N, Kobayashi S, et al. Significance of RRM1 and ERCC1 expression in resectable pancreatic adenocarcinoma. Oncogene 2009; 28:2903 - 9; http://dx.doi.org/10.1038/onc.2009.158; PMID: 19543324
   PubMed Web of Science ®Google Scholar
• Reynolds C, Obasaju C, Schell MJ, Li X, Zheng Z, Boulware D, et al. Randomized phase III trial of gemcitabine-based chemotherapy with in situ RRM1 and ERCC1 protein levels for response prediction in non-small-cell lung cancer. J Clin Oncol 2009; 27:5808 - 15; http://dx.doi.org/10.1200/JCO.2009.21.9766; PMID: 19884554
   PubMed Web of Science ®Google Scholar
• Rodriguez J, Boni V, Hernández A, Bitarte N, Zarate R, Ponz-Sarvisé M, et al. Association of RRM1 -37A>C polymorphism with clinical outcome in colorectal cancer patients treated with gemcitabine-based chemotherapy. Eur J Cancer 2011; 47:839 - 47; http://dx.doi.org/10.1016/j.ejca.2010.11.032; PMID: 21220199
   PubMed Web of Science ®Google Scholar
• Jordheim LP, Sève P, Trédan O, Dumontet C. The ribonucleotide reductase large subunit (RRM1) as a predictive factor in patients with cancer. Lancet Oncol 2011; 12:693 - 702; http://dx.doi.org/10.1016/S1470-2045(10)70244-8; PMID: 21163702
   PubMed Web of Science ®Google Scholar
• Burnett JC, Rossi JJ, Tiemann K. Current progress of siRNA/shRNA therapeutics in clinical trials. Biotechnol J 2011; 6:1130 - 46; http://dx.doi.org/10.1002/biot.201100054; PMID: 21744502
   PubMed Web of Science ®Google Scholar
• de Fougerolles AR. Delivery vehicles for small interfering RNA in vivo. Hum Gene Ther 2008; 19:125 - 32; http://dx.doi.org/10.1089/hum.2008.928; PMID: 18257677
   PubMed Web of Science ®Google Scholar
• Reid G, Wallant NC, Patel R, Antonic A, Saxon-Aliifaalogo F, Cao H, et al. Potent subunit-specific effects on cell growth and drug sensitivity from optimised siRNA-mediated silencing of ribonucleotide reductase. J RNAi Gene Silencing 2009; 5:321 - 30; PMID: 19771229
   PubMedGoogle Scholar
• Xie FY, Woodle MC, Lu PY. Harnessing in vivo siRNA delivery for drug discovery and therapeutic development. Drug Discov Today 2006; 11:67 - 73; http://dx.doi.org/10.1016/S1359-6446(05)03668-8; PMID: 16478693
   PubMed Web of Science ®Google Scholar
• Werth S, Urban-Klein B, Dai L, Höbel S, Grzelinski M, Bakowsky U, et al. A low molecular weight fraction of polyethylenimine (PEI) displays increased transfection efficiency of DNA and siRNA in fresh or lyophilized complexes. J Control Release 2006; 112:257 - 70; http://dx.doi.org/10.1016/j.jconrel.2006.02.009; PMID: 16574264
   PubMed Web of Science ®Google Scholar
• Aigner A. Gene silencing through RNA interference (RNAi) in vivo: strategies based on the direct application of siRNAs. J Biotechnol 2006; 124:12 - 25; http://dx.doi.org/10.1016/j.jbiotec.2005.12.003; PMID: 16413079
   PubMed Web of Science ®Google Scholar
• Urban-Klein B, Werth S, Abuharbeid S, Czubayko F, Aigner A. RNAi-mediated gene-targeting through systemic application of polyethylenimine (PEI)-complexed siRNA in vivo. Gene Ther 2005; 12:461 - 6; http://dx.doi.org/10.1038/sj.gt.3302425; PMID: 15616603
   PubMed Web of Science ®Google Scholar
• Ibrahim AF, Weirauch U, Thomas M, Grünweller A, Hartmann RK, Aigner A. MicroRNA replacement therapy for miR-145 and miR-33a is efficacious in a model of colon carcinoma. Cancer Res 2011; 71:5214 - 24; http://dx.doi.org/10.1158/0008-5472.CAN-10-4645; PMID: 21690566
   PubMed Web of Science ®Google Scholar
• Lee Y, Vassilakos A, Feng N, Jin H, Wang M, Xiong K, et al. GTI-2501, an antisense agent targeting R1, the large subunit of human ribonucleotide reductase, shows potent anti-tumor activity against a variety of tumors. Int J Oncol 2006; 28:469 - 78; PMID: 16391803
   PubMed Web of Science ®Google Scholar
• Fan H, Huang A, Villegas C, Wright JA. The R1 component of mammalian ribonucleotide reductase has malignancy-suppressing activity as demonstrated by gene transfer experiments. Proc Natl Acad Sci U S A 1997; 94:13181 - 6; http://dx.doi.org/10.1073/pnas.94.24.13181; PMID: 9371820
   PubMed Web of Science ®Google Scholar
• Mitsuno M, Kitajima Y, Ohtaka K, Kai K, Hashiguchi K, Nakamura J, et al. Tranilast strongly sensitizes pancreatic cancer cells to gemcitabine via decreasing protein expression of ribonucleotide reductase 1. Int J Oncol 2010; 36:341 - 9; PMID: 20043067
   PubMed Web of Science ®Google Scholar
• Duxbury MS, Ito H, Zinner MJ, Ashley SW, Whang EE. RNA interference targeting the M2 subunit of ribonucleotide reductase enhances pancreatic adenocarcinoma chemosensitivity to gemcitabine. Oncogene 2004; 23:1539 - 48; http://dx.doi.org/10.1038/sj.onc.1207272; PMID: 14661056
   PubMed Web of Science ®Google Scholar
• Gandhi V, Plunkett W. Modulatory activity of 2′,2′-difluorodeoxycytidine on the phosphorylation and cytotoxicity of arabinosyl nucleosides. Cancer Res 1990; 50:3675 - 80; PMID: 2340517
   PubMed Web of Science ®Google Scholar
• Heinemann V, Hertel LW, Grindey GB, Plunkett W. Comparison of the cellular pharmacokinetics and toxicity of 2′,2′-difluorodeoxycytidine and 1-beta-D-arabinofuranosylcytosine. Cancer Res 1988; 48:4024 - 31; PMID: 3383195
   PubMed Web of Science ®Google Scholar
• Huang P, Chubb S, Hertel LW, Grindey GB, Plunkett W. Action of 2′,2′-difluorodeoxycytidine on DNA synthesis. Cancer Res 1991; 51:6110 - 7; PMID: 1718594
   PubMed Web of Science ®Google Scholar
• Bouffard DY, Laliberté J, Momparler RL. Kinetic studies on 2′,2′-difluorodeoxycytidine (Gemcitabine) with purified human deoxycytidine kinase and cytidine deaminase. Biochem Pharmacol 1993; 45:1857 - 61; http://dx.doi.org/10.1016/0006-2952(93)90444-2; PMID: 8494545
   PubMed Web of Science ®Google Scholar
• Zhou J, Oliveira P, Li X, Chen Z, Bepler G. Modulation of the ribonucleotide reductase-antimetabolite drug interaction in cancer cell lines. J Nucleic Acids 2010; 2010:597098; http://dx.doi.org/10.4061/2010/597098; PMID: 20976259
   PubMedGoogle Scholar
• Dimitrova M, Affolter C, Meyer F, Nguyen I, Richard DG, Schuster C, et al. Sustained delivery of siRNAs targeting viral infection by cell-degradable multilayered polyelectrolyte films. Proc Natl Acad Sci U S A 2008; 105:16320 - 5; http://dx.doi.org/10.1073/pnas.0800156105; PMID: 18922784
   PubMed Web of Science ®Google Scholar